



**INNOVATIVE MEDICINES INITIATIVE
STAKEHOLDER FORUM 2011
12 MAY 2011 – SYMA CENTRE, BUDAPEST**

AGENDA

08:30 onwards Registration

**09:00 – 10:30 IMI Stakeholder Networking Breakfast
Hall A, Level 3, Melbourne Room**

**IMI Knowledge Management Workgroup Meeting (invitation only)
Hall A, Level 3, Rome Room**

10:30 – 10:45 Break

**Morning session – Joint Plenary - Part 1, Hall B, Plenary Room
Remote Monitoring - New opportunities for Chronic Disease Management
Presented by the European Commission (DG INFSO)**

Europe’s population is ageing; chronic diseases are growing, while, at the same time, the workforce is shrinking. How will health systems respond to these challenges and remain sustainable? eHealth and telemedicine offer some solutions to these challenges: for example, through remote monitoring and telehealth hospitals, doctors can reach patients and their homes at a distance, even across national borders. The session will provide an opportunity to present the main messages of the conference declaration, and there will be a debate between stakeholders on its relevance, particularly in relation to remote monitoring as a tool for chronic disease management and telehealth. The panel is also expected to give its view on how the declaration can be made operational in real life.

10:45 – 11:30

Chair: *Prof Martin R Cowie, Professor of Cardiology, Imperial College (Royal Brompton Hospital) London - European Society of Cardiology, United Kingdom*

Panel: *Prof. Dr. Péter Ofner, Director General, Hungarian Institute of Cardiology, Hungary*

Christoph Westerteicher, COCIR Telemedicine Focus Group Co-chair & Business Director EU TeleHealth, Philips Healthcare, Home Healthcare Solutions

Inge van den Broek, Consultant, De Hart&Vaatgroep; Patients Association for Cardiovascular Diseases



INNOVATIVE MEDICINES INITIATIVE

STAKEHOLDER FORUM 2011

12 MAY 2011 – SYMA CENTRE, BUDAPEST

Morning session – Joint Plenary - Part 2, Hall B, Plenary Room *Knowledge and Data Management for innovation in Drug Development*

How novel collaborative approaches in knowledge and data management will enable innovation in drug development for better health and more effective research. How public-private partnerships will facilitate shared knowledge.

Chair: *Prof. Michel Goldman, Executive Director (Innovative Medicines Initiative)*

11:30 Unlock the value of Health Information for better research and improved health
Mr. Romain Rutten, Vice President, Health Information Sciences (Johnson & Johnson - Janssen Research & Development)

11:50 Model-based approaches and decision making in drug development
Dr. Oscar Della Pasqua, Director, Clinical Pharmacology (GlaxoSmithKline)

12:10 Knowledge management in IMI: present and future
Ann Martin, Principal Scientific Officer, (Innovative Medicines Initiative)

12:15 – 13:45 Lunch - Exhibition Floor, Hall A, Ground Level

Afternoon Session 1 – Hall C, Ground Level, Room C4 *IMI meets the challenges of innovation in the pharmaceutical sector*

How IMI offers unique possibilities for collaboration and cooperation illustrated with seven on-going projects with emphasis on data sharing and knowledge management.

13:45 Welcome and Introductory remarks
Prof. Michel Goldman, Executive Director (IMI)

13:50 News from ongoing projects
PROTECT, eTOX, U-BIOPRED, PharmaTrain
Mr. Xavier Kurz, Prof. Ferran Sanz, Prof. Yi-Ke Guo, Dr. Anthony Rowe, Prof. Sandor Kerpel-Fronius

Questions & Answers
Moderator: Prof. Michel Goldman, Executive Director (IMI)



INNOVATIVE MEDICINES INITIATIVE

STAKEHOLDER FORUM 2011

12 MAY 2011 – SYMA CENTRE, BUDAPEST

14:30 Recent projects on knowledge management
DDMoRE, Open PHACTS, EHR4CR
Dr. Lutz Harnisch, Dr. Barend Mons, Dr. Andreas Schmidt

15:00 Questions & Answers
Moderator: Ann Martin, Principal Scientific Officer (IMI)

15:15 - 15:30 Break

Afternoon Session 2 – Hall C, Ground Level, Room C4 What is coming next at IMI - Part 1

To discuss with stakeholders how IMI's activities contribute to the 'Innovation Union' through promoting unprecedented collaboration between key actors within the European biopharmaceutical sector. How IMI projects will address the future needs of this sector.

15:30 Research and Innovation
Dr. Alain Vanvossel, Adviser, Directorate-General Research & Innovation (European Commission)

15:45 The Industry priorities
Mr. Richard Bergström, Director General, (EFPIA)

16:00 The Vision of the IMI Scientific Committee
Prof. Christian Nöe, Head of Medicinal Chemistry, (University of Vienna), Chair of IMI Scientific Committee

16:15 Questions & Answers
Moderator: Prof Goldman, Executive Director (IMI)

16:30 - 17:00 Coffee Break, Exhibition Floor, Hall A, Ground Level

Afternoon Session 3 – Hall C, Ground Level, Room C4 What is coming next at IMI - Part 2

To continue to discuss with IMI stakeholders what the future holds in terms of IMI's activities. An opportunity to discuss how certain challenges for successful consortia have been dealt with and which represent invaluable 'lessons learned' for IMI.

17:00 The IMI 4th Call for proposals
Ms. Magda Chlebus, RDG Acting Director (EFPIA)



INNOVATIVE MEDICINES INITIATIVE

STAKEHOLDER FORUM 2011

12 MAY 2011 – SYMA CENTRE, BUDAPEST

17:15

How to assemble a successful consortium

Round table discussion with contributions from

eTOX, RAPP-ID, DDMORE, Pharmatrain

Prof. Ferran Sanz, Dr. Jorge Villacian, Matt Aldridge (CEO, Mango Business Solutions Ltd), Prof. Sandor Kerpel-Fronius and Magali Poinot, Legal Manager (IMI)

Moderator: Professor Goldman, Executive Director (IMI)

17:45

Questions & Answers

18:00

Closing of the IMI Stakeholder Forum